3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Head & Neck
2
CNS
2
Sarcoma
1
NET
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Trastuzumab
87
Cyclophosphamide
67
Capecitabine
67
Paclitaxel
64
Docetaxel
58
Fulvestrant
52
Letrozole
50
Carboplatin
42
pembrolizumab
41
Lapatinib
38
Doxorubicin
36
Anastrozole
32
Vinorelbine
31
Bevacizumab
31
exemestane
28
Tamoxifen
25
Gemcitabine
25
Albumin-Bound Paclitaxel
25
Radiotherapy
21
Taxes
19
atezolizumab
18
pertuzumab
17
Everolimus
17
130-nm albumin-bound paclitaxel
17
Epirubicin
16
palbociclib
15
Magnetic Resonance Spectroscopy
15
eribulin
14
Ado-Trastuzumab Emtansine
14
Goserelin
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
alectinib
×
Breast
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts